GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tildrakizumab   Click here for help

GtoPdb Ligand ID: 8093

Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
Approved drug Immunopharmacology Ligand
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EU EMA (2018)  |  US FDA (2018)
International Nonproprietary Names Click here for help
INN number INN
9672 tildrakizumab
Synonyms Click here for help
Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 450
Other databases
GtoPdb PubChem SID 249565773
Search PubMed clinical trials tildrakizumab
Search PubMed titles tildrakizumab
Search PubMed titles/abstracts tildrakizumab
Wikipedia Tildrakizumab